HK1248111B - N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt - Google Patents

N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt Download PDF

Info

Publication number
HK1248111B
HK1248111B HK18107632.9A HK18107632A HK1248111B HK 1248111 B HK1248111 B HK 1248111B HK 18107632 A HK18107632 A HK 18107632A HK 1248111 B HK1248111 B HK 1248111B
Authority
HK
Hong Kong
Prior art keywords
compound
pharmaceutical composition
hemisulfate salt
composition according
salt
Prior art date
Application number
HK18107632.9A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1248111A1 (en
Inventor
Richard Roberts Daniel
Raymond Schartman Richard
Wei Chenkou
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1248111(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HK1248111A1 publication Critical patent/HK1248111A1/en
Publication of HK1248111B publication Critical patent/HK1248111B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18107632.9A 2012-02-27 2018-06-12 N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt HK1248111B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
US201261603598P 2012-02-27

Publications (2)

Publication Number Publication Date
HK1248111A1 HK1248111A1 (en) 2018-10-12
HK1248111B true HK1248111B (en) 2020-04-17

Family

ID=47844498

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107632.9A HK1248111B (en) 2012-02-27 2018-06-12 N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt

Country Status (26)

Country Link
US (1) US8759372B2 (enExample)
EP (2) EP3254681B1 (enExample)
JP (2) JP6208154B2 (enExample)
KR (2) KR102076118B1 (enExample)
CN (1) CN104136437B (enExample)
AU (1) AU2013226361B2 (enExample)
BR (1) BR112014021032B1 (enExample)
CA (1) CA2865585C (enExample)
CY (2) CY1119448T1 (enExample)
DK (2) DK2820016T3 (enExample)
EA (1) EA025358B1 (enExample)
ES (2) ES2746031T3 (enExample)
HK (1) HK1248111B (enExample)
HR (2) HRP20171620T1 (enExample)
HU (2) HUE034936T2 (enExample)
IL (1) IL234272B (enExample)
LT (2) LT2820016T (enExample)
MX (1) MX352171B (enExample)
NO (1) NO2935439T3 (enExample)
PL (2) PL2820016T3 (enExample)
PT (2) PT3254681T (enExample)
RS (2) RS56556B1 (enExample)
SG (1) SG11201404834XA (enExample)
SI (2) SI2820016T1 (enExample)
SM (1) SMT201700489T1 (enExample)
WO (1) WO2013130402A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211929B2 (en) 2012-01-26 2016-05-26 Christopher J. Soares Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2016144918A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
SG11201901457TA (en) 2016-09-07 2019-03-28 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL295609B2 (en) * 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
US20220249471A1 (en) * 2019-06-14 2022-08-11 The Regents Of The University Of California New therapeutic approach to lung disease
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2558274A1 (en) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative
CA2583536A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
DE602005027230D1 (de) 2004-10-22 2011-05-12 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
EP2007763A2 (en) 2006-04-10 2008-12-31 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato

Also Published As

Publication number Publication date
HUE047050T2 (hu) 2020-04-28
HUE034936T2 (hu) 2018-03-28
PT3254681T (pt) 2019-10-01
KR102076118B1 (ko) 2020-02-11
LT2820016T (lt) 2017-10-25
ES2642737T3 (es) 2017-11-17
BR112014021032B1 (pt) 2022-09-27
KR102220969B1 (ko) 2021-02-25
IL234272B (en) 2018-10-31
JP2015511581A (ja) 2015-04-20
EP2820016B1 (en) 2017-08-02
PT2820016T (pt) 2017-10-18
DK3254681T3 (da) 2019-09-30
CN104136437B (zh) 2016-05-11
CY1119448T1 (el) 2018-03-07
EA025358B1 (ru) 2016-12-30
RS56556B1 (sr) 2018-02-28
LT3254681T (lt) 2019-09-25
DK2820016T3 (da) 2017-11-13
EP3254681B1 (en) 2019-06-19
NO2935439T3 (enExample) 2018-03-31
AU2013226361B2 (en) 2017-09-21
EA201491585A1 (ru) 2015-01-30
SMT201700489T1 (it) 2017-11-15
SI2820016T1 (sl) 2017-11-30
CA2865585C (en) 2019-12-10
EP3254681A1 (en) 2017-12-13
KR20140130140A (ko) 2014-11-07
CA2865585A1 (en) 2013-09-06
CY1122121T1 (el) 2020-11-25
JP2017226693A (ja) 2017-12-28
JP6476253B2 (ja) 2019-02-27
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
AU2013226361A1 (en) 2014-10-16
CN104136437A (zh) 2014-11-05
BR112014021032A2 (enExample) 2017-06-20
MX352171B (es) 2017-11-13
US20130225636A1 (en) 2013-08-29
JP6208154B2 (ja) 2017-10-04
EP2820016A1 (en) 2015-01-07
WO2013130402A1 (en) 2013-09-06
ES2746031T3 (es) 2020-03-04
SG11201404834XA (en) 2014-09-26
KR20200016993A (ko) 2020-02-17
HRP20171620T1 (hr) 2017-12-01
SI3254681T1 (sl) 2019-10-30
HRP20191655T1 (hr) 2019-12-13
US8759372B2 (en) 2014-06-24
PL3254681T3 (pl) 2019-12-31
RS59295B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3254681B1 (en) N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
HK1248111A1 (en) N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
EP2629777B1 (en) Bicyclic diamines as janus kinase inhibitors
JP6777652B2 (ja) 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物
EP3917925B1 (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
JP2022545923A (ja) Ａ２ａ／ａ２ｂ阻害剤としてのトリアゾロピリミジン
CN110028509A (zh) 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
CN111094273B (zh) 催产素受体抑制剂的晶型及其制备方法
CN111094272B (zh) 一种otr抑制剂的可药用盐、晶型及制备方法
EP4079725A1 (en) N-carboxamidopyrazoline derivative serving as p2x3 receptor antagonist and applications
TW202340167A (zh) 含硫異吲哚啉類衍生物的晶型
WO2023202706A1 (zh) 硒杂环类化合物的盐型和晶型及其应用
CN120518607A (zh) 并环类衍生物抑制剂、其制备方法和应用
HK40064199A (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
HK40064199B (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors